Christine Parseghian

Trials

Studies that name Christine Parseghian as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:33 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT06412198 · A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

  M.D. Anderson Cancer Center · recruiting · Metastatic Colorectal Cancer, KRAS G12C Mutations · principal investigator
• Ph2
  NCT06369259 · Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

  M.D. Anderson Cancer Center · recruiting · Advanced Colorectal Cancer · principal investigator
• Ph1
  NCT05985954 · Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

  M.D. Anderson Cancer Center · recruiting · Metastatic Colorectal Cancer · principal investigator
• Ph2
  NCT03087071 · Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

  M.D. Anderson Cancer Center · active not recruiting · EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.